Fosun Kite

About Fosun Kite Biotechnology Co, Ltd. As a joint venture of Shanghai Fosun Pharmaceutical (Group) Co, Ltd and U.S. Kite Pharma, Fosun Kite Biotechnology Co, Ltd.(hereinafter referred as "Fosun Kite") was established in April 2017 in Shanghai China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. In early 2017, Fosun Kite brought in the world’s first approved CAR-T therapy for NHL Axicabtagene ciloleucel (US trade name Yescarta) from Kite Pharma (project name FKC876). Having obtained the comprehensive technology transfer and commercial license, the company has built a class B+A clean cell preparation base which is up to the latest GMP standards and in line with Kite’s commercial production standards and plant design concept. In August 2018, FKC876 officially obtained the Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA), and now is carrying out registrational clinical trials strictly following GCP and other regulatory requirements in China to provide evidence in support of its successful registration. In January 2019, a commercial manufacture base of settled in South Zhangjiang for commercial production of CAR-T therapies including FKC876 following registration. Besides Yescarta, Fosun Kite also collaborates with leading immunotherapy R&D organizations at home and abroad to build a rich and independent R&D pipeline.